-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Posts Q1 Loss $-0.29
7:09AM ET 5/05/2022 MT Newswires...
...
Omega Therapeutics (OMGA) said Friday it appointed Joshua Reed as chief financial officer, effective May 23. Reed, who was most recently CFO of Aldeyra...
Aldeyra Therapeutics (ALDX) has an average rating of buy and price targets ranging from $10 to $30, according to analysts polled by Capital IQ. (MT...
Aldeyra Therapeutics (ALDX) said Tuesday that it has finalized enrollment in the late-stage trial of 0.25% reproxalap ophthalmic solution in individuals...
Address | 131 Hartwell Avenue Lexington, Massachusetts 02421 |
Phone | +1.781.761.4904 |
Number of Employees | 19 |
Recent SEC Filing | 05/18/2022![]() |
President, Chief Executive Officer & Director | Todd C. Brady |
Chief Financial Officer, Treasurer & VP-Finance | Bruce Greenberg |
Senior Vice President-Clinical Development | James A. Gow |
Chief Development Officer | Stephen G. Machatha |
Price Open | $2.62 |
Previous Close | $2.46 |
52 Week Range | $2.36 - 13.18 |
Market Capitalization | $143.4 M |
Shares Outstanding | 58.3 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 08/04/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | N/A |
Earnings per Share | -$1.11 |
Beta vs. S&P 500 | N/A |
Revenue | $0.00 |
Net Profit Margin | N/A |
Return on Equity | -29.78% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |